Dutch health tech startup HEMEO was selected as one of only ten innovative companies to participate in the ScaleNL, NBSO LA, Cedars-Sinai Accelerator program in Los Angeles, USA. This prestigious opportunity places HEMEO among a select group of firms poised to make significant inroads into the U.S. healthcare market.

As the leading health system in California and a pioneer in the American healthcare landscape, Cedars-Sinai offers a robust platform for startups to gain invaluable insights and connections. ScaleNL, a public-private partnership, supports Dutch tech companies in scaling their U.S. operations, while the Netherlands Business Support Office (NBSO) in Los Angeles collaborates with the Dutch Consulate General in San Francisco, focusing on the Western States, including California.

During the program, which was attended by Professor Aamer Ahmed, HEMEO’s Chief Medical Officer, HEMEO managed to enhance its visibility and expand its network with mentors, investors and potential customers. This program also provided crucial insights into the U.S. context, providing a deeper understanding about raising capital in the U.S. marketplace. This directly helps HEMEO hone its value proposition and ROI strategy, while validating its product-market fit with key healthcare stakeholders. Furthermore, the program facilitated connections with key opinion leaders, subject matter experts and other healthcare entrepreneurs, fostering the exchange of best practices.

HEMEO also benefited from the deeper understanding gained of the regulatory environment and the payor landscape. Insights into Cedars-Sinai’s electronic medical record system (EPIC) were particularly valuable, as was exploring potential integration opportunities. The company also learned about various operational and clinical departments at Cedars-Sinai.

This program marks a significant milestone, positioning HEMEO for successful entry and growth in the competitive U.S. healthcare market.